PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 30, 2025Addiction Science & Clinical PracticeOpen Access

Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol

View Full Paper
Ask AI
Bookmark
Share

Authors

CFChristopher S. FreetKSKirsten ShulerSKSarah Kawasaki

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Freet et al. (2025) studied this question.

synapsesocial.com/papers/6a6337fc621d213327b6e162https://doi.org/10.1186/s13722-025-00618-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder2024 · 18 citations
  2. 2Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder2020 · 1,013 citations
  3. 3Agreement between self‐reported illicit drug use and biological samples: a systematic review and meta‐analysis2023 · 126 citations